Pacira BioSciences

Pacira BioSciences is a holding company. Through its subsidiaries, the company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its proprietary DepoFoam? extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. The company's marketed product, EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, the company's proprietary technology that delivers bupivacaine over time for extended analgesia.
  • TickerPCRX
  • ISINUS6951271005
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

EXPAREL® Reduced Opioid Use After Oral Surgery

Liana Moussatos ...
  • Shveta Dighe

MAA Filed for EXPAREL®/Postsurgical Analgesia; CHMP Opinion Expected in H2:20

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

ValuEngine Rating and Forecast Report for PCRX

With a more favourable environment, PACIRA BIOSCIENCES INCO. improves to Slightly Positive

PACIRA BIOSCIENCES INCO. (US), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 18, 2019, the closing price was USD 43.77 and its potential was estimated at USD 51.81.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch